Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Investor Presentation (June 2021)
24 slides from Elixinol Wellness's investor presentation, June 2021
Slide 1: Investor Presentation: Strategic Plan Development
Strategic Plan Development ASX:EXL | OTCQB:ELLXF Investor Presentation June 2021 Kind of Amazing
Slide 2: Disclaimer
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Disclaimer This presentation contains summary information about Elixinol Global Limited (Elixinol Wellness) and its subsidiaries and their activities. The information in this presentation does not purport to be comp
Slide 3: Our Vision and Our Mission
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Elixinol CBD Our Vision Building a global, natural health and wellness consumer products business. elixinolSkin CBD Our Mission Making a positive contribution to people’s health, wellness and the planet through the
Slide 4: Our year of transformation in review
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Our year of transformation in review • +18% growth on prior • Good Mood CBD quarter gummies launch • Tighter COVID restrictions • Board + Management team changes – Oliver • UK drives growth with new • COVID-19 conti
Slide 5: Rebranding to Elixinol Wellness
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 We’ve been a wellness company all along. Rebranding ourselves to Elixinol Wellness is a natural yet symbolic step in our journey of creating a global wellness consumer products business that makes a positive contrib
Slide 6: FY2020 financial summary
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 FY2020 financial summary Well funded, reduced cost base and refocused on building a profitable consumer goods business. Annualised cost base 45% Substantial operational and corporate cost reduction program completed
Slide 7: Key highlights of Q1 FY2021
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Key highlights of Q1 FY2021 Whilst Q1 results have been impacted by COVID restrictions and seasonality, we’ve seen a gradual revenue improvement month over month, improved gross margins, further reduced cost and adv
Slide 8: Elixinol brand health US
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Elixinol brand health US Elixinol is perceived as a high quality and effective brand that compares favourably against the market leader. The brand relaunch and re-positioning has materially improved the brand’s bran
Slide 9: Evolved brand positioning
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Evolved brand positioning To create stronger emotional engagement with consumers, Elixinol will launch the ‘Let Nature Shine campaign’ connecting our heritage of sourcing the best from nature through hemp with today
Slide 10: Growth through innovation
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Growth through innovation We’ve developed our portfolio across all regions to improve our product offering, attract new customers and ‘premiumise’ our brands. Natural wellness for people and the planet 10
Slide 11: Digital strategy driving results across all regions
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Digital strategy driving results across all regions Investment in digital and e-commerce capability is showing positive results across all business units. Revenues from e-commerce in Q1 accounted for 40% of total Gr
Slide 12: Global CBD market outlook & regulations
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Global CBD market outlook & regulations The global CBD is projected for sustained long-term growth. Regulations are changing fast and in favour of CBD but will create transitionary volatility. Gradual recovery from
Slide 13: Acquisition of CannaCare Health to create a leading Pan-European CBD business
Strategic Plan Development ASX:EXL | OTCQB:ELLXF Acquisition of CannaCare Health to create a leading Pan-European CBD business Announced on 15 March 2021 Kind of Amazing
Slide 14: CannaCare overview
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 CannaCare overview CannaCare presents an opportunity to take a significant share of Europe’s fastest growing CBD market. • Established 2018, • Extensive product • CANOBO #1 brand • CANOBO first • Capital light model
Slide 15: Early skincare success
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Early skincare success Skincare range launch in April achieved extensive distribution and early re-orders. Canobo skincare is Mueller’s best selling new cosmetic line. Extensive integrated media campaign results • P
Slide 16: Synergies and growth outlook
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Synergies and growth outlook An acquisition of CannaCare will deliver Elixinol immediate material scale in Germany, while creating significant long-term value through a high growth market trend, identified cost syne
Slide 17: Key people
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Key people FRANK OTTO OLIVER HAIST Strategy Partner & Shareholder Managing Director Serial founder in the media industry L’Oréal – Group Key Account Manager FMCG Founder and investor of many successful Philips – Int
Slide 18: Transaction summary
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Transaction summary Elixinol plans to acquire leading German-based CBD business, CannaCare with acquisition expected to fast-track revenue growth and accelerate pathway to group profitability Attractive, EBITDA accr
Slide 19: Financial Implications
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Financial Implications The following sets out some key effects to the Company as a result of the Proposed Transaction proceeding: 1 Elixinol Group financial statements for year ended 31 December 2020 (audited). Annu
Slide 20: Performance since March
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Performance since March CannaCare’s performance in Germany has been consistent with our expectations, supported by a successful skincare launch The combination of CannaCare with Elixinol’s UK business is expected to
Slide 21: Timetable
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 Timetable Event Date Despatch of Notice Of Meeting to shareholders Thursday, 15 April 2021 (including Independent Expert’s Report) Annual General Meeting Monday, 17 May 2021 Targeted transaction completion Monday, 5
Slide 22: What's next…
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 What’s next… Our core priorities are to re-ignite our US and UK businesses following severe COVID restrictions, integrate CannaCare into the Elixinol Group whilst fuelling the Canobo growth, further shifting our bus
Slide 23: In summary
Elixinol Wellness Limited (ASX:EXL, OTCQB:ELLXF) | Investor Presentation | June 2021 In summary…the new Our brands are Continued Well positioned strong and business in global CBD getting stronger transformation in markets repositioning and a better economic with new scale in innovation is leading en
Slide 24: Thank You!
Annual General Meeting – May 2021 Thank You! Let Nature Shine ASX:EXL | OTCQB:ELLXF 24
Elixinol Wellness — Investor Presentation (June 2021) on 6ix